Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20331761 | 1.00 | TTK (0.41) | TTKCCNA2CDK2FGFR4KDM4E | |
| SCHEMBL29577295 | 0.93 | TTK (0.37) | TTKCCNA2CDK2TP53 | |
| SCHEMBL21240326 | 0.93 | TTK (0.37) | TTKCCNA2CDK2TP53 | |
| SCHEMBL21240135 | 0.91 | PDE9A (0.34) | TTKFGFR4KDM4ETP53 | |
| SCHEMBL29577336 | 0.91 | PDE9A (0.34) | TTKFGFR4KDM4ETP53 | |
| SCHEMBL29577170 | 0.89 | TTK (0.37) | TTKCCNA2CDK2FGFR4FGFR1 | |
| SCHEMBL20331105 | 0.89 | TTK (0.37) | TTKCCNA2CDK2FGFR4FGFR1 | |
| SCHEMBL20331966 | 0.88 | TTK (0.37) | TTKCCNA2CDK2 | |
| SCHEMBL20331753 | 0.88 | FGFR4 (0.33) | TTKFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL29578207 | 0.88 | FGFR4 (0.33) | TTKFGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-11-03 | — | — | US | disclosed |
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348573-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | TTK 3915/4885CCNA2 3817/4885CDK2 801/4885 |
| US-11555036-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | TTK 3818/4885CCNA2 3885/4885CDK2 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.